by Rawamino | Oct 31, 2025 | Peptides
Introduction The interleukin-23 (IL-23) signaling axis is central to immune modulation, influencing chronic inflammatory responses and maintaining Th17-cell activity. Overactivation of this pathway is implicated in inflammatory skin conditions, where persistent...
by Rawamino | Oct 30, 2025 | Peptides
Introduction Aging remains one of the most significant biological risk factors associated with neurodegenerative conditions. Across the lifespan, progressive molecular alterations—ranging from mitochondrial decline to chronic low-grade inflammation—create a cellular...
by Rawamino | Oct 30, 2025 | Peptides
Introduction Synucleinopathies such as Parkinson’s disease (PD), dementia with Lewy bodies, and multiple system atrophy are characterized by abnormal aggregation of α-synuclein (αSyn) within neuronal and glial compartments. Mounting evidence suggests that soluble...
by Rawamino | Oct 29, 2025 | Peptides
Introduction Alzheimer’s disease (AD) remains defined by progressive cognitive decline, synaptic failure, and characteristic proteinopathies that include extracellular amyloid-β (Aβ) deposits and intraneuronal tau aggregates. The “amyloid cascade” framework posits...
by Rawamino | Oct 29, 2025 | Peptides
Introduction Alzheimer’s disease (AD) is marked by network-level cognitive decline emerging from convergent cellular stressors, including proteostasis failure (Aβ and tau misfolding), chronic neuroinflammatory signaling, synaptic dysfunction, and impaired adult...
by Rawamino | Oct 29, 2025 | Peptides
Introduction Biochemical analyses indicated that Cdk5i binds more strongly to the Cdk5/p25 complex than to Cdk5 alone, reflecting its targeted affinity for the pathological form of the kinase. Alzheimer’s disease (AD) represents a complex neurodegenerative disorder...